Capricor Therapeutics (CAPR) EBIT Margin (2011 - 2024)
Capricor Therapeutics (CAPR) posted quarterly EBIT Margin of 69.15% for Q4 2024, down 5855.0% year-over-year from 1.2% in Q1 2024, and up 87.98% quarter-over-quarter from 575.24% in Q3 2024.
Capricor Therapeutics (CAPR) EBIT Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' EBIT Margin history runs 13 years deep, the most recent figure standing at 69.15% for Q4 2024.
- In Q4 2024, EBIT Margin fell 5855.0% year-over-year to 69.15%; the TTM figure through Sep 2025 stood at 778.78% (down 65114.0% YoY), while the FY2024 annual figure was 191.12%, down 9549.0% from the prior year.
- EBIT Margin for Q4 2024 stood at 69.15%, up from 575.24% in the prior quarter.
- The five-year high for EBIT Margin was 10.6% in Q4 2023, with the low at 23211.04% in Q3 2020.
- The 5-year median for EBIT Margin is 491.12% (2022), against an average of 3536.55%.
- The sharpest annual moves came in 2020 and 2021: EBIT Margin plunged 2206537 bps in 2020, then jumped 450397 bps in 2021.
- Capricor Therapeutics' EBIT Margin stood at 7229.02% in 2020, then jumped by 66 bps to 2490.75% in 2021, then surged by 66 bps to 840.33% in 2022, then surged by 99 bps to 10.6% in 2023, then plunged by 552 bps to 69.15% in 2024.
- Business Quant data shows CAPR's EBIT Margin at 69.15% in Q4 2024, 575.24% in Q3 2024, and 291.86% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -69.15% |
| Sep 30, 2024 | -575.24% |
| Jun 30, 2024 | -291.86% |
| Mar 31, 2024 | -102.66% |
| Dec 31, 2023 | -10.60% |
| Sep 30, 2023 | -110.97% |
| Jun 30, 2023 | -197.76% |
| Mar 31, 2023 | -274.04% |
| Dec 31, 2022 | -840.33% |
| Sep 30, 2022 | -407.00% |
| Jun 30, 2021 | -2,490.75% |
| Mar 31, 2021 | -12,644.77% |
| Dec 31, 2020 | -7,229.02% |
| Sep 30, 2020 | -23,211.04% |
| Jun 30, 2020 | -6,994.72% |
| Mar 31, 2020 | -1,134.94% |
| Dec 31, 2019 | -667.88% |
| Sep 30, 2019 | -1,145.67% |
| Jun 30, 2019 | -503.39% |
| Mar 31, 2019 | -1,109.38% |